AU2003269050A1 - Method for decreasing bioavailability variability of an orally administered medicine - Google Patents

Method for decreasing bioavailability variability of an orally administered medicine

Info

Publication number
AU2003269050A1
AU2003269050A1 AU2003269050A AU2003269050A AU2003269050A1 AU 2003269050 A1 AU2003269050 A1 AU 2003269050A1 AU 2003269050 A AU2003269050 A AU 2003269050A AU 2003269050 A AU2003269050 A AU 2003269050A AU 2003269050 A1 AU2003269050 A1 AU 2003269050A1
Authority
AU
Australia
Prior art keywords
orally administered
administered medicine
bioavailability variability
decreasing bioavailability
decreasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003269050A
Inventor
Armelle Brun
Corinne Degert
Rene Laversanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Publication of AU2003269050A1 publication Critical patent/AU2003269050A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2003269050A 2002-07-24 2003-07-23 Method for decreasing bioavailability variability of an orally administered medicine Abandoned AU2003269050A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0209369A FR2842734A1 (en) 2002-07-24 2002-07-24 METHOD FOR DECREASING THE VARIABILITY OF THE BIOAVAILABILITY OF AN ORAL MEDICINAL PRODUCT AND ORAL PHARMACEUTICAL COMPOSITIONS
FR02/09369 2002-07-24
PCT/FR2003/002322 WO2004010977A1 (en) 2002-07-24 2003-07-23 Method for decreasing bioavailability variability of an orally administered medicine

Publications (1)

Publication Number Publication Date
AU2003269050A1 true AU2003269050A1 (en) 2004-02-16

Family

ID=30011429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003269050A Abandoned AU2003269050A1 (en) 2002-07-24 2003-07-23 Method for decreasing bioavailability variability of an orally administered medicine

Country Status (3)

Country Link
AU (1) AU2003269050A1 (en)
FR (1) FR2842734A1 (en)
WO (1) WO2004010977A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052436B1 (en) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 Extended release tablet formulations containing pramipexole or pharmaceutically acceptable salts thereof, methods of preparation and uses thereof
EP2669002A1 (en) * 2005-01-28 2013-12-04 Japan Science and Technology Agency Molecular aggregate capable of undergoing phase transition by dehydrating condensation and method of phase transition thereof
EP1857112B1 (en) * 2005-03-09 2013-05-15 Sunstar Inc. Anticancer composition comprising liposomes containing phytosterols
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
HUE055000T2 (en) 2015-02-27 2021-10-28 Dechra Ltd Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
CN108578382B (en) * 2018-05-15 2021-05-11 华中科技大学鄂州工业技术研究院 Liquid crystal nanogel capsule for treating colon cancer and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675998B1 (en) * 1991-05-03 1995-03-10 Oreal PROCESS FOR IMPROVING THE THERAPEUTIC EFFECTIVENESS OF LIPOSOLUBLE ANTIFUNGAL AGENTS OF THE IMIDAZOLE FAMILY AND COMPOSITION FOR CARRYING OUT SAID METHOD.
FR2803202B1 (en) * 2000-01-03 2004-04-16 Capsulis PHARMACEUTICAL COMPOSITIONS FOR ORAL DELIVERY

Also Published As

Publication number Publication date
WO2004010977A1 (en) 2004-02-05
FR2842734A1 (en) 2004-01-30

Similar Documents

Publication Publication Date Title
AU2003211376A1 (en) Drug administration method
AU2003272590A1 (en) Method for ophtalmic administration of medicament
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
EP1478345A4 (en) Novel pharmaceutical dosage forms and method for producing same
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
AU2003303633A1 (en) Fast dissolving films for oral administration of drugs
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2002319653A1 (en) Method for oral drug delivery
AU2003233464A1 (en) Lipid mediated screening of drug candidates for identification of active compounds
AU2003901813A0 (en) Pharmaceutical derivatives
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
EP1585500B8 (en) Coated particles for sustained-release pharmaceutical administration
AU2003276572A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
AU2003223420A1 (en) System and method of determining an individualized drug administration dosage
AU2002950657A0 (en) Derivatives of monosaccharides for drug discovery
AU2003276688A1 (en) Pharmaceutical composition of metaxalone with enhanced oral bioavailability
AU2003269050A1 (en) Method for decreasing bioavailability variability of an orally administered medicine
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
IL166450A0 (en) Drug discovery method
HK1173795A1 (en) Drug discovery method
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2003263480A1 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase